News | September 12, 2022
Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)